Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 41 for your search:
Drug:
exemestane
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Aromatase Inhibitor Clinical Trial
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
40 to 70
Sponsor:
NIGMS
Protocol IDs:
0412-14
, UO1-GM61373-06, NCT00228956
2.
Phase II/III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI
Protocol IDs:
ACOSOG-Z1031
, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
3.
Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
not specified
Sponsor:
Other
Protocol IDs:
N07MAN
, Eudract 2007-007030-20, NCT00684216
4.
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
65 and over
Sponsor:
Other
Protocol IDs:
0120070323
, NCT00698971
5.
Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-2402
, BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
6.
Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-25-02
, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28
7.
Phase III Randomized Study of Exemestane in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Phase:
Phase III
Type:
Prevention
Status:
Active
Age:
35 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
CAN-NCIC-MAP3
, PFIZER-EXEAPO-0028-150, ExCel, NCT00083174, MAP3
8.
Aromasin vs Arimidex Study As Initial Hormonal Therapy in Postmenopausal Women With Advanced/Recurrent Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A5991048
, NCT00143390
9.
Phase III Randomized Study of Fulvestrant With Versus Without Anastrozole Versus Exemestane Alone in Postmenopausal Women With Estrogen Receptor and/or Progesterone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Relapsed or Progressed During Prior Treatment With Nonsteroidal Aromatase Inhibitors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
ICR-CTSU-SOFEA
, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
10.
Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
ECOG-PACCT-1
, SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
11.
Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
GIM-3-FATA
, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086
12.
Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GIM-GIM8-OVER
, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194
13.
Phase III Randomized Study of Adjuvant Endocrine Therapy Comprising Letrozole, Anastrazole, or Exemestane Versus Tamoxifen Citrate in Postmenopausal Women With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
COL-MNEMOSYNE
, MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, NCT00893061
14.
Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Alone Versus Ovarian Function Suppression and Tamoxifen Citrate Versus Ovarian Function Suppression and Exemestane in Premenopausal Women Who Have Undergone Surgery for Hormone Receptor-Positive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
Other
Protocol IDs:
ICORG-06-02
, ICORG 06-02, IBCSG 24-02, SOFT, BIG 2-02, EUDRACT-2004-000166-13, EU-20916, NCT00917969
15.
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CRAD001Y2301
, EUDRACT Number: 2008-008698-69, NCT00863655
16.
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
Other
Protocol IDs:
SHBCC0701
, NCT00902954
17.
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
9238UK/0005
, NCT00944918
18.
Phase I/II Randomized Pilot Study of Neoadjuvant Therapy Comprising Sunitinib Malate and Exemestane in Postmenopausal Women With Hormone Receptor-Positive and HER-2 Negative Primary Breast Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
Other
Protocol IDs:
ICO-SUT-EXE-08
, SUT-EXE-08, PFIZER-ICO-SUT-EXE-08, NCT00931450
19.
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
H 24786 / EXTENT
, NCT00905021
20.
Phase II Study of Exemestane in Postmenopausal Women at High Risk for Invasive Breast Cancer
Phase:
Phase II
Type:
Prevention
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI
Protocol IDs:
GUMC-2007-313
, NCI-04-C-0044, NCT00085072, GUMC-2007-313, GT 07-313, 2007-313
21.
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
OSU-0245
, NCT00201773
22.
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
OSU-0494
, NCT00201864
23.
Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2002521-01H
, NCT00261027
24.
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A4021004
, NCT00372996
25.
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
GEICAM/2006-03
, NCT00432172
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
